Literature DB >> 9574863

Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia.

C Bouwer1, D J Stein.   

Abstract

BACKGROUND: There is increasing evidence that social phobia responds to treatment with selective serotonin reuptake inhibitors (SSRIs). However, the efficacy of citalopram, the most selective of the SSRIs, in social phobia has not been well documented.
METHODS: Citalopram was used on an open-label naturalistic basis in 22 social phobia patients presenting for treatment (40 mg daily for 12 weeks). Patients were rated with the Liebowitz Social Anxiety Scale and the Clinical Global Impressions (CGI) scale.
RESULTS: Ratings on the Liebowitz Social Anxiety Scale and the CGI were significantly improved after treatment. A total of 86% of patients were responders at week 12. LIMITATION: Open, uncontrolled study.
CONCLUSIONS: Citalopram appears to be effective in the treatment of social phobia. A controlled trial is warranted to confirm these data. The role of serotonin in social phobia deserves further study.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9574863     DOI: 10.1016/s0165-0327(97)00182-1

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  9 in total

Review 1.  Social anxiety disorder : current treatment recommendations.

Authors:  Jacqueline E Muller; Liezl Koen; Soraya Seedat; Dan J Stein
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 2.  A review of the epidemiology and approaches to the treatment of social anxiety disorder.

Authors:  L Sareen; M Stein
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

Review 3.  Social anxiety disorder: recent findings in the areas of epidemiology, etiology, and treatment.

Authors:  C Blanco; K Nissenson; M R Liebowitz
Journal:  Curr Psychiatry Rep       Date:  2001-08       Impact factor: 5.285

Review 4.  Citalopram--a review of pharmacological and clinical effects.

Authors:  K Bezchlibnyk-Butler; I Aleksic; S H Kennedy
Journal:  J Psychiatry Neurosci       Date:  2000-05       Impact factor: 6.186

5.  Antioxidant enzyme and malondialdehyde values in social phobia before and after citalopram treatment.

Authors:  Murad Atmaca; E Tezcan; M Kuloglu; B Ustundag; H Tunckol
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-08       Impact factor: 5.270

6.  Current management of obsessive and phobic states.

Authors:  Serena Goljevscek; Livia A Carvalho
Journal:  Neuropsychiatr Dis Treat       Date:  2011-09-30       Impact factor: 2.570

7.  Psychopharmacology of anxiety disorders.

Authors:  Giovanni B Cassano; Nicolò Baldini Rossi; Stefano Pini
Journal:  Dialogues Clin Neurosci       Date:  2002-09       Impact factor: 5.986

8.  Comparison of treatment adherence between selective serotonin reuptake inhibitors and moclobemide in patients with social anxiety disorder.

Authors:  Se-Won Lim; Yong-Seok Kwon; Juwon Ha; Hyeng-Geun Yoon; Seung-Min Bae; Dong-Won Shin; Young-Chul Shin; Kang-Seob Oh
Journal:  Psychiatry Investig       Date:  2012-01-18       Impact factor: 2.505

9.  Synthesis and Antimicrobial Screening of Novel 4-Substituted Phenyl-5-[1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-yl]-2H-1,2,4-triazole-3-thiones.

Authors:  Namratha Bhandari; Santosh L Gaonkar
Journal:  Int Sch Res Notices       Date:  2014-11-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.